- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 249/06 - Triazoles-1, 2, 3Triazoles-1, 2, 3 hydrogénés avec des radicaux aryle liés directement aux atomes du cycle
Détention brevets de la classe C07D 249/06
Brevets de cette classe: 642
Historique des publications depuis 10 ans
|
47
|
57
|
43
|
59
|
45
|
46
|
52
|
35
|
33
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Bristol-myers Squibb Company | 4863 |
24 |
| Centre National de La Recherche Scientifique | 10102 |
16 |
| Janssen Pharmaceutica N.V. | 3612 |
12 |
| F. Hoffmann-La Roche AG | 7942 |
11 |
| Institut Curie | 560 |
10 |
| Universite de Montpellier | 960 |
10 |
| The Regents of the University of California | 19517 |
9 |
| Bayer Cropscience AG | 2138 |
9 |
| Siemens Medical Solutions USA, Inc. | 1540 |
8 |
| Roche Diagnostics Operations, Inc. | 1434 |
7 |
| Takeda Pharmaceutical Company Limited | 2943 |
7 |
| Imago Biosciences, Inc. | 37 |
7 |
| The University of Queensland | 657 |
7 |
| E. I. du Pont de Nemours and Company | 4249 |
6 |
| FMC Corporation | 852 |
6 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 160 |
6 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2838 |
6 |
| Yale University | 2289 |
6 |
| Sigilon Therapeutics, Inc. | 90 |
6 |
| Pfizer Inc. | 3368 |
5 |
| Autres propriétaires | 464 |